Therapeutic Lithium Levels
For acute mania, maintain serum lithium levels between 1.0-1.5 mEq/L (mmol/L), and for long-term maintenance therapy, target 0.6-0.8 mEq/L (mmol/L), with blood drawn 12 hours post-dose. 1
Target Levels by Clinical Phase
Acute Mania Treatment
- Target range: 1.0-1.5 mEq/L 1
- Typically achieved with 600 mg three times daily 1
- Monitor serum levels twice weekly until stabilized 1
- Higher tolerance for lithium exists during acute manic episodes 1
Maintenance/Long-term Control
- Standard target: 0.6-0.8 mEq/L 1, 2, 3
- Usually maintained with 300 mg three to four times daily 1
- This range balances efficacy with tolerability across most clinical practice guidelines 3
Flexible Dosing Strategy
If using the standard 0.6-0.8 mEq/L range 2:
- Reduce to 0.4-0.6 mEq/L if patient shows good response but experiences poor tolerance
- Increase to 0.8-1.0 mEq/L if response is insufficient and patient tolerates the medication well
Age-Specific Adjustments
Older Adults (≥60 years)
Target 0.4-0.6 mEq/L as the initial range 4, 5:
- Ages 65-79: May increase to maximum 0.7-0.8 mEq/L if needed 2
- Ages ≥80: Maximum 0.7 mEq/L 2
- Mean levels in older adults typically range 0.47-0.67 mEq/L 5
- Levels of 0.82-1.0 mEq/L associated with increased side effects in this population 5
- Age-related reduction in renal clearance necessitates lower targets 5
Children and Adolescents
- Not recommended under age 12 1
- For ages ≥12: No clear consensus exists, though majority opinion supports similar ranges as adults (0.6-0.8 mEq/L) 2
Critical Monitoring Protocol
Timing of Blood Draws
Draw blood samples 8-12 hours after the last dose when lithium concentrations are at steady-state trough 1, 6:
- For once-daily dosing: Draw at 24 hours post-dose 6
- This standardization is essential for accurate interpretation
Monitoring Frequency
Acute Phase:
- Twice weekly until serum level and clinical state stabilize 1
Maintenance Phase:
- Every 2 months minimum for uncomplicated cases 1
- Every 3 months for stable patients 7, 6
- Every 8-10 weeks for elderly patients 4
Baseline Laboratory Assessment
Before initiating lithium 7:
- Complete blood count
- Thyroid function tests (TSH, free T4)
- Renal function: BUN, creatinine, calculate GFR
- Urinalysis
- Serum calcium
- Pregnancy test in females of childbearing age
Ongoing Laboratory Monitoring
Every 3-6 months 7:
- Lithium level
- Renal function (creatinine, GFR)
- Thyroid function
- Urinalysis
Toxicity Thresholds
Early Toxicity Signs
Patients may show toxicity at 1.0-1.5 mEq/L if abnormally sensitive 1:
- Diarrhea
- Vomiting
- Tremor
- Mild ataxia
- Drowsiness
- Muscular weakness
Instruct patients to discontinue lithium immediately and contact physician if these symptoms occur 1
Overt Toxicity
- Levels >1.2 mEq/L carry significant toxicity risk 1, 5
- Levels of 1.2-1.25 mEq/L are overtly toxic in older adults 5
Critical Clinical Pitfalls
Drug Interactions Requiring Closer Monitoring
These medications reduce lithium clearance and increase toxicity risk 1, 5:
- Diuretics (especially thiazides)
- ACE inhibitors
- NSAIDs (including COX-2 inhibitors like celecoxib, which can increase lithium levels by ~17%) 1
- Monitor lithium levels more frequently when initiating or discontinuing these medications
Renal Function Considerations
- GFR <45 mL/min/1.73 m²: Do not initiate lithium in older adults 4
- GFR <30 mL/min/1.73 m²: Obtain nephrology consultation and critically re-evaluate continuation 4
- Renal insufficiency is a relative contraindication 6
Conditions Requiring Dose Adjustment
Temporary reduction or cessation may be needed with 1:
- Protracted sweating or diarrhea (administer supplemental fluid and salt)
- Concurrent infection with fever
- Sodium depletion (maintain normal diet with adequate salt and 2500-3000 mL fluid intake daily)
Key Clinical Principle
Do not rely solely on serum levels—accurate patient evaluation requires both clinical assessment and laboratory analysis 1. The therapeutic window is narrow, and individual sensitivity varies considerably, particularly in elderly patients who often require lower doses and exhibit toxicity at levels tolerated by younger adults 1.